Anaplastic Thyroid Cancer
What's New
Last Posted: May 13, 2024
- Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis.
Jonathan N Priantti, et al. Endocrine 2024 0 - Combination BRAFV600E inhibition with the multitargeting tyrosine kinase inhibitor axitinib shows additive anticancer activity in BRAFV600E-mutant anaplastic thyroid cancer.
Viswanath Gunda, et al. Thyroid : official journal of the American Thyroid Association 2023 0 - Molecular genetics of diffuse sclerosing papillary thyroid cancer.
Alswailem Meshael, et al. The Journal of clinical endocrinology and metabolism 2023 0 - Anaplastic Thyroid Cancer in Sicily: The Role of Environmental Characteristics.
Tavarelli Martina, et al. Frontiers in endocrinology 2017 0 277 - GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer.
Murugan Avaniyapuram Kannan, et al. Oncotarget 2019 0 (41) 4107-4124 - Everolimus in Anaplastic Thyroid Cancer: A Case Series.
Harris Ethan J, et al. Frontiers in oncology 2019 0 106 - Identification of Targetable Lesions in Anaplastic Thyroid Cancer by Genome Profiling.
Ravi Naveen, et al. Cancers 2019 0 (3) - EIF1AX c.338-2A>T splice site mutation in a patient with trabecular adenoma and cytological indeterminate lesion.
Castagna Maria Grazia, et al. Archives of endocrinology and metabolism 2020 0 (2) 185-189 - Analysis of ALK, IDH1, IDH2 and MMP8 somatic mutations in differentiated thyroid cancers.
Murugan Avaniyapuram Kannan, et al. Molecular and clinical oncology 2021 0 (4) 210 - Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.
Hanna Glenn J, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2018 0 (7) 1546-1553
More
About Rare Diseases PHGKB
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Content Summary
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Eclampsia
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Glomerulonephritis
- Graves Disease
- Hemophilia
- Huntington Disease
- Microcephaly
- Myasthenia Gravis
- Phenylketonuria
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Content source: